Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: Implications for dyskinesia

Experimental Neurology

Volumn 185, Issue 1, 2004, Pages 36-46

  Ravenscroft, Paula ^a,c   Chalon, Sylvie ^b   Brotchie, Jonathan M ^a,d   Crossman, Alan R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSERM   (France)

^c Williams House   (United Kingdom)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Dynorphin; Dyskinesia; Enkephalin; L DOPA; Parkinson's disease; PPE A; PPE B; Ropinirole

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA; MESSENGER RNA; OPIATE PEPTIDE; PREPROENKEPHALIN; PREPROENKEPHALIN A; PRODYNORPHIN; PROTEIN PRECURSOR; ROPINIROLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; MALE; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TOPOGRAPHY;

EID: 0346363680     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.09.001     Document Type: Article

References (53)

1. Angulo J.A. Involvement of dopamine D1 and D2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J. Neurochem. 58:1992;1104-1109.
2. Baik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., Le Meur M., Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 377:1995;424-428.
3. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21:2001;6853-6861.
4. Chalon S., Emond P., Bodard S., Vilar M.P., Thiercelin C., Besnard J.C., Guilloteau D. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse. 31:1999;134-139.
5. Coldwell M.C., Boyfield I., Brown T., Hagan J.J., Middlemiss D.N. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 127:1999;1696-1702.
6. Cole D.G., Kobierski L.A., Konradi C., Hyman S.E. 6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9631-9635.
7. Cole R.L., Konradi C., Douglass J., Hyman S.E. Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron. 14:1995;813-823.
8. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R., Love P.E., Ooi G.T., Grinberg A., Lee E.J., Huang S.P. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12564-12568.
9. Drago J., Gerfen C.R., Westphal H., Steiner H. D1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience. 74:1996;813-823.
10. Dragunow M., Robertson G.S., Faull R.L., Robertson H.A., Jansen K. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294.
11. Duty S., Brotchie J.M. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp. Neurol. 144:1997;423-432.
12. Duty S., Henry B., Crossman A.R., Brotchie J.M. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 150:1998;223-234.
13. Eden R.J., Costall B., Domeney A.M., Gerrard P.A., Harvey C.A., Kelly M.E., Naylor R.J., Owen D.A., Wright A. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav. 38:1991;147-154.
14. Engber T.M., Susel Z., Kuo S., Gerfen C.R., Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552:1991;113-118.
15. Fukuzaki K., Kamenosono T., Kitazumi K., Nagata R. Effects of ropinirole on motor behavior in MPTP-treated common marmosets. Pharmacol. Biochem. Behav. 67:2000;121-129.
16. Fukuzaki K., Kamenosono T., Nagata R. Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys. Pharmacol. Biochem. Behav. 65:2000;503-508.
17. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
18. Gerfen C.R., McGinty J.F., Young W.S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11:1991;1016-1031.
19. Gerfen C.R., Keefe K.A., Gauda E.B. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J. Neurosci. 15:1995;8167-8176.
20. Granata R., Wenning G.K., Jolkkonen J., Jenner P., Marsden C.D. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. J. Neural Transm. 103:1996;249-260.
21. Harrison M.B., Kumar S., Hubbard C.A., Trugman J.M. Early changes in neuropeptide mRNA expression in the striatum following reserpine treatment. Exp. Neurol. 167:2001;321-328.
22. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine- lesioned rat. Exp. Neurol. 155:1999;204-220.
23. Henry B., Fox S.H., Crossman A.R., Brotchie J.M. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 171:2001;139-146.
24. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
25. Huang K.X., Walters J.R. Dopaminergic regulation of AP-1 transcription factor DNA binding activity in rat striatum. Neuroscience. 75:1996;757-775.
26. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 80:1995;225-236.
27. Jaber M., Fournier M.C., Bloch B. Reserpine treatment stimulates enkephalin and D2 dopamine receptor gene expression in the rat striatum. Brain Res. Mol. Brain Res. 15:1992;189-194.
28. Jaber M., Tison F., Fournier M.C., Bloch B. Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res. Mol. Brain Res. 23:1994;14-20.
29. Jaber M., Normand E., Bloch B. Effect of reserpine treatment on enkephalin mRNA level in the rat striatum: an in situ hybridization study. Brain Res. Mol. Brain Res. 32:1995;156-160.
30. Jolkkonen J., Granata R., Jenner P., Marsden C.D. Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum. Neuropeptides. 29:1995;109-114.
31. Kashihara K., Akiyama K., Ishihara T., Shiro Y., Shohmori T. Levodopoa but not bromocriptine induces AP-1 and creb DNA-binding activity in the dopamine-depleted striatum of the rat. Life Sci. 58:1996;PL159-PL170.
32. Konradi C., Cole R.L., Heckers S., Hyman S.E. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J. Neurosci. 14:1994;5623-5634.
33. McGeorge A.J., Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537.
34. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bedard P.J., Di Paolo T. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res. Mol. Brain Res. 49:1997;55-62.
35. Morissette M., Grondin R., Goulet M., Bedard P.J., Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 72:1999;682-692.
36. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 40:1990;340-345.
37. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13-18.
38. Parent A., Asselin M.C., Cote P.Y. Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys. Adv. Neurol. 69:1996;73-77.
39. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, London.
40. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord. 13:1998;234-241.
41. Prikhojan A., Brannan T., Yahr M.D. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats. J. Neural Transm. 107:2000;1159-1164.
42. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342:2000;1484-1491.
43. Reavill C., Boyfield I., Coldwell M., Nelson P. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats. J. Pharm. Pharmacol. 52:2000;1129-1135.
44. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
45. Robertson G.S., Vincent S.R., Fibiger H.C. Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos. Brain Res. 523:1990;288-290.
46. Robertson G.S., Vincent S.R., Fibiger H.C. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience. 49:1992;285-296.
47. Steiner H., Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp. Brain Res. 123:1998;60-76.
48. Steiner H., Gerfen C.R. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience. 88:1999;795-810.
49. Taylor M.D., De Ceballos M.L., Rose S., Jenner P., Marsden C.D. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4- dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur. J. Pharmacol. 219:1992;183-192.
50. Tulloch I.F. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology. 49:1997;S58-S62.
51. Whone A., Watts R., Stoessl A., Davis M., Reske S., Nahmias C., Lang A., Rascol O., Ribeiro M., Remy P., Poewe W., Hauser R., Brooks D. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54:2003;93-101.
52. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 79:1994;729-742.
53. Zeng B.Y., Jolkkonen J., Jenner P., Marsden C.D. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine- lesioned rat. Neuroscience. 66:1995;19-28.